Search results for "liver-disease"

showing 10 items of 21 documents

Budesonide in previously untreated autoimmune hepatitis

2005

Background: Autoimmune hepatitis (AIH) is a chronic liver disease that is effectively treated with immunosuppressive therapy. Predniso(lo)ne, often in combination with azathioprine, is the basic therapeutic option to induce remission. However, this regimen can cause numerous side effects. The aim of the present study was to evaluate budesonide as a treatment option in the induction of remission in patients with previously untreated AIH. Methods: Between October 1998 and August 1999, 12 patients were treated with 3 mg budesonide thrice daily for 3 months in this open one-arm multicenter phase IIa study. Primary end point was induction of remission indicated by a drop of aspartate aminotransf…

BudesonideAdultMalemedicine.medical_specialtybudesonideAzathioprinePREDNISOLONEAutoimmune hepatitisChronic liver diseaseGastroenterologyInflammatory bowel diseaseLiver diseaseLIVER-DISEASEInternal medicinemedicineHumansAgedHepatologyautoimmune hepatitisbusiness.industryCHRONIC ACTIVE HEPATITISCORTICOSTEROID-THERAPYAlanine TransaminaseMiddle Agedmedicine.diseaseCROHNS-DISEASERegimenHepatitis AutoimmuneImmunologyPrednisoloneFemaleTRIALORAL BUDESONIDEbusinesstreatment optionsmedicine.drugINFLAMMATORY-BOWEL-DISEASELiver international
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct

Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet.

2015

Contains fulltext : 155347.pdf (Publisher’s version ) (Closed access) BACKGROUND/OBJECTIVES: In the context of obesity, epigenetic mechanisms regulate cell-specific chromatin plasticity, perpetuating gene expression responses to nutrient excess. MacroH2A1, a variant of histone H2A, emerged as a key chromatin regulator sensing small nutrients during cell proliferation and differentiation. Mice genetically ablated for macroH2A1 (knockout (KO)) do not show overt phenotypes under a standard diet. Our objective was to analyse the in vivo role of macroH2A1 in response to nutritional excess. METHODS: Twelve-week-old whole-body macroH2A1 KO male mice were given a high-fat diet (60% energy from lard…

EXPRESSIONCHROMATINNonalcoholic steatohepatitisModels Molecularmedicine.medical_specialtyHISTONE VARIANT MACROH2Amacrohistone H2A1 High fat diet obesity.Endocrinology Diabetes and MetabolismLIVER-DISEASE NAFLDTHERMOGENESISMedicine (miscellaneous)Adipose tissueBiologyDiet High-FatCell LineHistonesMiceINFLAMMATIONAdipose Tissue BrownThinnessInternal medicineBINDINGmedicineAnimalsGenetic ablationNutrition and DieteticsAdipogenesisNONALCOHOLIC STEATOHEPATITISTRANSCRIPTIONAL COREGULATOR PELP1medicine.diseaseNUTRITION&DIETETICSObesityDisease Models AnimalRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]EndocrinologyEnergy expenditureFat dietOBESITYInsulin ResistanceEnergy MetabolismThermogenesisInternational journal of obesity (2005)
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity

2004

Abstract Objectives We sought to assess the age-specific prevalence of oral lichen planus (OLP) in Mediterranean patients with chronic hepatitis C virus (HCV) and to evaluate the features of OLP in relation to sex, smoking, HCV genotype, HIV-1 coinfection, and antiviral treatments. Methods In all, 178 anti-HCV-positive adults (60 women and 118 men; age range 20-66 years) recruited from two cohorts (104 HIV-negative patients and 74 patients with HIV coinfection) underwent oral examination. Results Overall prevalence of OLP was 2.8% (5 of 178) (male/female ratio 0.2; odds ratio=0.119; 95% confidence interval=0.013-1.106), only among HIV-negative participants, always in the reticular pattern, …

Liver CirrhosisMaleHepacivirusHIV Infectionsclinical-featureComorbidityHepacivirusmedicine.disease_causeCohort Studieschemistry.chemical_compoundPrevalenceMedicineExtrahepatic manifestationbiologySmokingvirus diseasesMiddle AgedHepatitis CCoinfectionFemalegeneral-populationmedicine.drugAdultmedicine.medical_specialtyGenotypeHepatitis C virushuman-immunodeficiency-viruDermatologyHCV hyperendemic areaAntiviral AgentsFlaviviridaeAge Distributionstomatognathic systemInternal medicineHumansInterferon alfaAgedbusiness.industryRibavirinChronic active hepatitiOdds ratiomedicine.diseasebiology.organism_classificationstomatognathic diseaseschemistrypositive patientsImmunologynegative patientliver-diseaseOral lichen planusinterferon therapybusinessLichen Planus Oral
researchProduct

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct

Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Mic…

2021

We have shown that prebiotic xylo-oligosaccharides (XOS) increased beneficial gut microbiota (GM) and prevented high fat diet-induced hepatic steatosis, but the mechanisms associated with these effects are not clear. We studied whether XOS affects adipose tissue inflammation and insulin signaling, and whether the GM and fecal metabolome explain associated patterns. XOS was supplemented or not with high (HFD) or low (LFD) fat diet for 12 weeks in male Wistar rats (n = 10/group). Previously analyzed GM and fecal metabolites were biclustered to reduce data dimensionality and identify interpretable groups of co-occurring genera and metabolites. Based on our findings, biclustering provides a use…

MaleDOWN-REGULATIONsuolistomikrobistoHealth Toxicology and Mutagenesismedicine.medical_treatmentOligosaccharidesPROTEINAdipose tissuelcsh:MedicineGut florabiclusteringGLUCOSE0302 clinical medicineAMINO-ACIDSxylo-oligosaccharidesaineenvaihduntametabolites2. Zero hungerINSULIN-RESISTANCE0303 health sciencesmicroRNAhigh fat diet1184 Genetics developmental biology physiology3142 Public health care science environmental and occupational health3. Good healthCHAIN FATTY-ACIDSAdipose TissueLiverB-CELLSOBESITY1181 Ecology evolutionary biology030211 gastroenterology & hepatologymedicine.symptommedicine.medical_specialtyInflammationBiologyDiet High-FatArticle03 medical and health sciencesMetabolomicsprebiootitLIVER-DISEASEInternal medicineMetabolomemedicineAnimalsbiochemistryRats Wistar1172 Environmental sciences030304 developmental biologyInflammationgut microbiotaPrebioticlcsh:RPublic Health Environmental and Occupational Healthnon-alcoholic fatty liver diseaseACETYL-COA CARBOXYLASEksylo-oligosakkariditbiology.organism_classificationmedicine.diseaserotta (laji)Fatty LiverratsInsulin receptorEndocrinologyei-alkoholiperäinen rasvamaksasairaus3121 General medicine internal medicine and other clinical medicinebiology.proteinaineenvaihduntatuotteetkoe-eläinmallitSteatosismikro-RNAInternational Journal of Environmental Research and Public Health
researchProduct

Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats

2020

Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…

MalesuolistomikrobistoPROGRESSIONBIFIDOBACTERIASTEATOHEPATITISNon-alcoholic Fatty Liver DiseaseCecumDiet Fat-RestrictedaineenvaihduntaFatty Acidsrasvamaksafood and beveragesmitochondriaLiverprebioticBody CompositionBIOPSIESFemaleOxidation-Reductionlcsh:Nutrition. Foods and food supplymitokondriotGlucuronateslcsh:TX341-641Diet High-Fatdigestive systemArticleDYSBIOSISprebiootitINFLAMMATIONLIVER-DISEASEINTESTINAL MICROBIOTAoligosaccharidesoligosakkariditAnimalsRats WistarTriglyceridesfatty livergut microbiotaFaecalibacterium prausnitziinutritional and metabolic diseasesLipid MetabolismGastrointestinal MicrobiomeRatsFAECALIBACTERIUM-PRAUSNITZIIGlucosePrebiotics416 Food Scienceaineenvaihduntatuotteet3111 BiomedicineEnergy IntakeEnergy MetabolismmetabolismNutrients
researchProduct

Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis

2010

Background: TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), has been linked to inflammatory pathways as well as bile homeostasis, and could therefore be involved in primary sclerosing cholangitis (PSC) a chronic inflammatory bile duct disease. We aimed to extensively investigate TGR5 sequence variation in PSC, as well as functionally characterize detected variants.Methodology/Principal Findings: Complete resequencing of TGR5 was performed in 267 PSC patients and 274 healthy controls. Six nonsynonymous mutations were identified in addition to 16 other novel single-nucleotide polymorphisms. To investigate the impact from the nonsynonymous variants on TGR5, we created a receptor mod…

Nonsynonymous substitutionMaleModels MolecularCandidate geneLinkage disequilibriumProtein ConformationDNA Mutational Analysislcsh:MedicineGenome-wide association studySUSCEPTIBILITYMULTIPLE SEQUENCE ALIGNMENTSReceptors G-Protein-CoupledMice0302 clinical medicineChildlcsh:ScienceGenetics and Genomics/Genetics of DiseaseGENE-EXPRESSIONGenetics0303 health sciencesMultidisciplinaryGastroenterology and Hepatology/Biliary TractCROHN-DISEASEMiddle AgedG protein-coupled bile acid receptor3. Good healthGenetics and Genomics/Gene FunctionULCERATIVE-COLITISChromosomes Human Pair 2WEB SERVER030211 gastroenterology & hepatologyFemaleResearch ArticleAdultAdolescentCholangitis SclerosingSingle-nucleotide polymorphismLocus (genetics)BiologyGenetics and Genomics/Complex TraitsPrimary sclerosing cholangitis03 medical and health sciencesYoung AdultDogsPROTEIN-COUPLED RECEPTORSLIVER-DISEASEmedicineAnimalsHumansAmino Acid SequenceBOWEL-DISEASE030304 developmental biologyAgedGastroenterology and Hepatology/Inflammatory Bowel DiseaseCYSTIC-FIBROSISlcsh:Rmedicine.diseaseGene Expression RegulationMutationCancer researchCattleColitis Ulcerativelcsh:Q
researchProduct